Acurx Pharmaceuticals, Inc. () Stock Analysis | Price, Returns, Financials & Key Metrics

Price Point

High/Low

1Day

52 Week

Valuation

Technical

Day's Volume

CASH

43.26 k

Shareholding (Mar 2025)

FII

0.16%

Held by 4 FIIs

DII

96.09%

Held by 4 DIIs

Promoter

0.00%

How big is Acurx Pharmaceuticals, Inc.?

22-Jun-2025

As of Jun 18, Acurx Pharmaceuticals, Inc. has a market capitalization of 19.27 million, with net sales of 0.00 million and a net profit of -11.87 million over the last four quarters. The company reported shareholder's funds of 0.62 million and total assets of 3.86 million as of Dec 24.

What does Acurx Pharmaceuticals, Inc. do?

22-Jun-2025

Acurx Pharmaceuticals, Inc. is a micro-cap company in the Pharmaceuticals & Biotechnology industry, currently reporting a net profit loss of $2 million and a market cap of $19.27 million. The company has no dividend yield and significant negative financial metrics.

Is Acurx Pharmaceuticals, Inc. technically bullish or bearish?

20-Sep-2025

As of August 29, 2025, Acurx Pharmaceuticals has a mildly bullish technical trend, with mixed indicators across timeframes, but it has significantly underperformed the S&P 500 with year-to-date and one-year returns of -73.34% and -88.98%, respectively.

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.Unlock 29 Markets

Dashboard

Unrated Stock - No Analysis Available

Mojo Parameters

Stock DNA

Industry

Pharmaceuticals & Biotechnology

Market cap

USD 7 Million ()

P/E

NA (Loss Making)

Industry P/E

Dividend Yield

0.00%

Debt Equity

-1.70

Return on Equity

-999,999.00%

Price to Book

1.83

Revenue and Profits:

Net Sales:

(Quarterly Results - Jun 2025)

Net Profit:

-2 Million

Total Returns

Total Returns (Price + Dividend)

TimePeriod

Price Return

Dividend Return

Total Return

3 Months

-16.04%

6 Months

-50.0%

1 Year

-80.92%

2 Years

-95.41%

3 Years

5.45%

4 Years

-95.81%

5 Years

0.0%

Acurx Pharmaceuticals, Inc. for the last several years.

Risk Adjusted Returns v/s

News & Corporate Actions

News

Is Acurx Pharmaceuticals, Inc. technically bullish or bearish?

As of 29 August 2025, the technical trend for Acurx Pharmaceuticals, Inc. has changed from bullish to mildly bullish. The weekly MACD indicates a mildly bullish stance, while the monthly MACD remains bearish. The RSI shows no signal on the weekly timeframe but is bullish on the monthly. Moving averages are bearish on the daily, and the KST is bearish across both weekly and monthly periods. The Dow Theory is mildly bearish on the weekly timeframe, with no trend on the monthly. The OBV is mildly bullish weekly but mildly bearish monthly. In terms of performance, Acurx has underperformed significantly compared to the S&P 500, with a year-to-date return of -73.34% versus the S&P's 12.22%, and a one-year return of -88.98% compared to the S&P's 17.14%. Overall, the current technical stance is mildly bullish, but the strength is tempered by bearish indicators in multiple timeframes....

No announcement available

Corporate Actions

No corporate action available

Key Factors

Quality key factors

Factor

Value

Sales Growth (5y)

0.00%

EBIT Growth (5y)

0.00%

EBIT to Interest (avg)

-4.48

Debt to EBITDA (avg)

Negative Net Debt

Net Debt to Equity (avg)

-2.01

Sales to Capital Employed (avg)

Tax Ratio

4.10%

Dividend Payout Ratio

Pledged Shares

Institutional Holding

22.15%

ROCE (avg)

ROE (avg)

Valuation key factors

Factor

Value

P/E Ratio

NA (Loss Making)

Industry P/E

Price to Book Value

3.53

EV to EBIT

-0.25

EV to EBITDA

-0.25

EV to Capital Employed

-1.50

EV to Sales

PEG Ratio

Dividend Yield

ROCE (Latest)

Negative Capital Employed

ROE (Latest)

-1708.19%

Technicals key factors

Indicator

Weekly

Monthly

MACD

Mildly Bullish

Bearish

RSI

Bearish

Bullish

Bollinger Bands

Bearish

Moving Averages

Bearish (Daily)

KST

Mildly Bullish

Bearish

Dow Theory

Mildly Bearish

Mildly Bullish

OBV

No Trend

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Shareholding

Shareholding Snapshot : Mar 2025

Shareholding Compare (%holding)

Majority shareholders

Domestic Funds

Held in 3 Schemes (3.75%)

Foreign Institutions

Held by 4 Foreign Institutions (0.16%)

Strategic Entities with highest holding

Highest Public shareholder

Financial

[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Jun'25 - YoY",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in quarter ended Jun 2025 is 0.00% vs 0.00% in Jun 2024",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in quarter ended Jun 2025 is 46.34% vs -20.59% in Jun 2024",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Jun'25",
        "Jun'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-2.30",
          "val2": "-4.10",
          "chgp": "43.90%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-2.20",
          "val2": "-4.10",
          "chgp": "46.34%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is 0.00% vs 0.00% in Dec 2023",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is 3.42% vs -20.66% in Dec 2023",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-14.10",
          "val2": "-14.60",
          "chgp": "3.42%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-14.10",
          "val2": "-14.60",
          "chgp": "3.42%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Consolidated) - Jun'25 - YoY

Jun'25

Jun'24

Change(%)

Net Sales

0.00

Operating Profit (PBDIT) excl Other Income

-2.30

-4.10

43.90%

Interest

0.00

Exceptional Items

0.00

Consolidate Net Profit

-2.20

-4.10

46.34%

Operating Profit Margin (Excl OI)

0.00%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in quarter ended Jun 2025 is 0.00% vs 0.00% in Jun 2024

Consolidated Net Profit

YoY Growth in quarter ended Jun 2025 is 46.34% vs -20.59% in Jun 2024

All Quarterly Results

Annual Results Snapshot (Consolidated) - Dec'24

Dec'24

Dec'23

Change(%)

Net Sales

0.00

Operating Profit (PBDIT) excl Other Income

-14.10

-14.60

3.42%

Interest

0.00

Exceptional Items

0.00

Consolidate Net Profit

-14.10

-14.60

3.42%

Operating Profit Margin (Excl OI)

0.00%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in year ended Dec 2024 is 0.00% vs 0.00% in Dec 2023

Consolidated Net Profit

YoY Growth in year ended Dec 2024 is 3.42% vs -20.66% in Dec 2023

All Annual Results

Company CV

About Acurx Pharmaceuticals, Inc.

Acurx Pharmaceuticals, Inc.

Pharmaceuticals & Biotechnology

No Details Available.

Company Coordinates

No Company Details Available

Acurx Pharmaceuticals, Inc.

1Day

52 Week

CASH

FII

DII

Promoter

How big is Acurx Pharmaceuticals, Inc.?

Watch in Real-Time

What does Acurx Pharmaceuticals, Inc. do?

Is Acurx Pharmaceuticals, Inc. technically bullish or bearish?

MarketsMojo — Loved in India, Now Global

Dashboard

Mojo Parameters

Stock DNA

Total Returns (Price + Dividend)

Risk Adjusted Returns v/s

News

Is Acurx Pharmaceuticals, Inc. technically bullish or bearish?

Announcements

Corporate Actions

Quality key factors

Valuation key factors

Technicals key factors

Shareholding Snapshot : Mar 2025

Shareholding Compare (%holding)

Quarterly Results Snapshot (Consolidated) - Jun'25 - YoY

Annual Results Snapshot (Consolidated) - Dec'24

About Acurx Pharmaceuticals, Inc.

Company Coordinates